OBJECTIVE: To explore the effect of multiple prothrombotic risk factors in individuals with anticardiolipin antibodies (aCL), we evaluated immunologic, coagulation, and genetic prothrombotic abnormalities in a cohort of individuals with different aCL titers. METHODS: We recruited 87 individuals into 4 categories (normal, low, intermediate, or high) based on their baseline IgG aCL (aCL-IgG) titers. We measured at followup: repeat aCL-IgG, IgM aCL (aCL-IgM), antibodies to beta2-glycoprotein I (anti-beta2-GPI), lupus anticoagulant (LAC) antibodies, protein C, protein S, activated protein C resistance, factor V506 Leiden mutation, methyl tetrahydrofolate reductase (MTHFR) C677T genotype, and prothrombin 20210A gene mutation. Thrombotic events were confirmed. RESULTS: At recruitment, 20 individuals were negative for aCL-IgG and 67 were positive (22 low, 20 intermediate, and 25 high titer). Twenty of the 87 participants had experienced a previous thrombotic event: 4 in the aCL-IgG negative group and 16 in the aCL-IgG positive group. Among the 87 individuals, the number of those with concomitant prothrombotic risk factors was as follows: 5 had no other prothrombotic risk factors, 32 had 1 risk factor, 24 had 2 risk factors, 10 had 3 risk factors, 10 had 4 risk factors, and 6 had 5 risk factors. Thrombotic events were observed in 20%, 13%, 33%, 10%, 30%, and 50% of these groups, respectively, and the odds ratio associated with a previous thrombotic event was 1.46 per each additional prothrombotic risk factor (95% confidence interval: 1.003-2.134). CONCLUSION: In individuals with positive aCL-IgG, we observed an association between the number of prothrombotic risk factors and history of thrombotic events.
OBJECTIVE: To explore the effect of multiple prothrombotic risk factors in individuals with anticardiolipin antibodies (aCL), we evaluated immunologic, coagulation, and genetic prothrombotic abnormalities in a cohort of individuals with different aCL titers. METHODS: We recruited 87 individuals into 4 categories (normal, low, intermediate, or high) based on their baseline IgG aCL (aCL-IgG) titers. We measured at followup: repeat aCL-IgG, IgM aCL (aCL-IgM), antibodies to beta2-glycoprotein I (anti-beta2-GPI), lupus anticoagulant (LAC) antibodies, protein C, protein S, activated protein C resistance, factor V506 Leiden mutation, methyl tetrahydrofolate reductase (MTHFR) C677T genotype, and prothrombin 20210A gene mutation. Thrombotic events were confirmed. RESULTS: At recruitment, 20 individuals were negative for aCL-IgG and 67 were positive (22 low, 20 intermediate, and 25 high titer). Twenty of the 87 participants had experienced a previous thrombotic event: 4 in the aCL-IgG negative group and 16 in the aCL-IgG positive group. Among the 87 individuals, the number of those with concomitant prothrombotic risk factors was as follows: 5 had no other prothrombotic risk factors, 32 had 1 risk factor, 24 had 2 risk factors, 10 had 3 risk factors, 10 had 4 risk factors, and 6 had 5 risk factors. Thrombotic events were observed in 20%, 13%, 33%, 10%, 30%, and 50% of these groups, respectively, and the odds ratio associated with a previous thrombotic event was 1.46 per each additional prothrombotic risk factor (95% confidence interval: 1.003-2.134). CONCLUSION: In individuals with positive aCL-IgG, we observed an association between the number of prothrombotic risk factors and history of thrombotic events.
Authors: J Voorberg; J Roelse; R Koopman; H Büller; F Berends; J W ten Cate; K Mertens; J A van Mourik Journal: Lancet Date: 1994-06-18 Impact factor: 79.321
Authors: B E Price; J Rauch; M A Shia; M T Walsh; W Lieberthal; H M Gilligan; T O'Laughlin; J S Koh; J S Levine Journal: J Immunol Date: 1996-09-01 Impact factor: 5.422
Authors: P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel Journal: Nat Genet Date: 1995-05 Impact factor: 38.330
Authors: R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma Journal: Nature Date: 1994-05-05 Impact factor: 49.962
Authors: K S Ginsburg; M H Liang; L Newcomer; S Z Goldhaber; P H Schur; C H Hennekens; M J Stampfer Journal: Ann Intern Med Date: 1992-12-15 Impact factor: 25.391
Authors: Carolyn Neville; Joyce Rauch; Jeannine Kassis; Susan Solymoss; Lawrence Joseph; Patrick Belisle; Jerrold S Levine; Paul R Fortin Journal: Thromb Haemost Date: 2009-01 Impact factor: 5.249
Authors: C Neville; J Rauch; J Kassis; S Solymoss; L Joseph; P Belisle; R Subang; E R Chang; P R Fortin Journal: Rheumatology (Oxford) Date: 2006-03-01 Impact factor: 7.580